Glenmark Pharma receives USFDA nod for Topiramate ER capsules

The approved product is a generic version of Qudexy capsules of Upsher-Smith Laboratories.

58
Medicine
Picture: Pixabay

Last Updated on February 5, 2021 by The Health Master

Glenmark Pharma has received final approval from the US health regulator for Topiramate extended-release capsules, used to treat certain types of seizures.

The approved product is a generic version of Qudexy capsules of Upsher-Smith Laboratories.

The company has received final approval from the United States Food and Drug Administration (USFDA) for Topiramate extended-release capsules USP in the strengths of 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg, Glenmark said in a regulatory filing.

Quoting IQVIA sales data for the 12-month period ended December 2020, Glenmark Pharmaceuticals said Qudexy extended-release capsules market achieved annual sales of approximately US $120 million.

The company’s current portfolio consists of 169 products authorised for distribution in the US market and 43 abbreviated new drug applications (ANDAs) pending approval with the US FDA.


Also read:

Granules India gets USFDA nod for Potassium Chloride Oral Solution

Glenmark gets USFDA nod for Amphetamine Sulfate tablets

Unichem gets USFDA nod for Zonisamide Capsules


The Health Master is now on Telegram. For latest update on health and Pharmaceuticals, subscribe to The Health Master on Telegram.

Follow and connect with us on Facebook and Linkedin

Go to main website, click here

Subscribe for daily free updates, click here

For daily free updates on WhatsApp, click here

Subscribe here for daily updates
Loading